Ultragenyx Pharmaceutical Stock Forecast
NASDAQ: RAREHealthcareBiotechnologyUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
RARE analyst consensus
Consensus (20 analysts)
buy
Avg. price target
$26.79+73.06%
- Strong buy 2
- Buy 8
- Hold 10
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 20 Wall Street analysts covering Ultragenyx Pharmaceutical (2026-10-10), 10 rate the stock a buy or strong buy, 10 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $26.79, with a high estimate of $39.00 and a low estimate of $16.00. The average target implies upside of 73.1% from the current price of $15.48.
The spread between the highest and lowest targets is 143.8%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for RARE.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 2 | 10% |
| Buy | 8 | 40% |
| Hold | 10 | 50% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-10.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $16.00 | +3.36% |
| Average target | $26.79 | +73.06% |
| High target | $39.00 | +151.94% |